APM
PHAS

Avidity Partners Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Avidity Partners Management’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,361,365
Closed -$768K – 113
2022
Q3 		$768K Sell
4,361,365
-43,635
-1% -$44.5K 0.02% 94
2022
Q2 		$2.64M Hold
4,405,000
– – 0.06% 69
2022
Q1 		$5.82M Hold
4,405,000
– – 0.12% 67
2021
Q4 		$11.5M Hold
4,405,000
– – 0.24% 61
2021
Q3 		$13.7M Buy
4,405,000
+90,000
+2% +$300K 0.3% 62
2021
Q2 		$16.1M Buy
4,315,000
+30,000
+0.7% +$99.9K 0.43% 58
2021
Q1 		$14.8M Buy
+4,285,000
New +$17.4M 0.41% 66

Other funds holding PHAS

DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Avidity Partners Management's PHAS Position: Q4 2022 in Review

Avidity Partners Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 4,361,365 shares — an estimated $768K sold.

Avidity Partners Management first reported a position in PHAS in Q1 2021 and held it in 7 quarters. The position peaked at $16.1M in Q2 2021. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

  • Avidity Partners Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Avidity Partners Management sold 4,361,365 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $768K.
  • Avidity Partners Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
  • Avidity Partners Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $16.1M in Q2 2021.
  • 5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Avidity Partners Management's 13F filing for Q4 2022, filed 14 Feb 2023.